13F Holdings
中文EN

HURA TuHURA Biosciences, Inc./NV

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20242024-06-30FY20242023-12-31FY20232023-06-30
Income statement
Revenue$0$0—$0—
R&D expense$20.53M$13.34M$2.66M$9.40M$9.31M
SG&A expense$7.58M$3.87M$5.79M$4.14M$5.49M
Interest expense$625,283$4.14M—$18,688—
Pretax income-$30.05M-$21.68M—$29.30M—
Income tax$1,600$3,768—$0—
Net income-$30.05M-$21.68M-$8.32M-$29.32M-$14.65M
EPS (basic)-0.63-1.21-0.32-2.47-9.27
EPS (diluted)-0.63-1.21—-2.47—
Weighted avg. shares (diluted)47.93M18.66M—11.89M—
Balance sheet
Cash & equivalents$3.62M$12.66M$12.31M$3.67M$1.53M
Current assets$4.62M$19.61M$5.53M$4.16M$3.27M
PP&E, net$300,639$123,366$674,000$182,170$709,000
Goodwill$10.74M————
Total assets$27.35M$19.97M$6.20M$4.36M$3.98M
Current liabilities$5.92M$5.33M$2.26M$3.60M$3.08M
Total liabilities$6.42M$5.37M$2.44M$5.92M$3.25M
Shareholders' equity$20.93M$14.59M-$6.96M-$1.56M$731,000
Shares outstanding59.34M12.17M—12.17M—
Cash flow statement
Operating cash flow-$27.63M-$14.73M-$7.18M-$11.95M-$11.87M
Capital expenditure$76,083$57,906—$79,224—
Free cash flow-$27.71M-$14.79M—-$12.03M—
Investing cash flow-$1.34M-$6.05M-$20,000-$1.30M-$232,000
Financing cash flow$19.93M$29.77M$10.57M$2.66M$1.85M
Depreciation & amortization$71,265$116,710$55,000$177,377$60,000
Stock-based compensation$6.42M$1.96M$607,000$478,890$1.49M
Share buybacks———$24,751—

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.